Home Featured Page 206

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties...

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as...

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

PT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of...

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

1...205206207...296 Page 206 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties...

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as...

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

PT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of...

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY